The Testosterone Trade-Off: Optimizing Anabolism Without the Needle

#1

In an era where male hormonal health is in decline and the temptation of Anabolic-Androgenic Steroids (AAS) is rising, a new review from the Mayo Clinic provides a critical appraisal of “natural” testosterone optimization. The central thesis is that testosterone (T) levels are not merely a product of genetics, but a dynamic readout of energy availability, environmental exposure, and recovery status. The authors argue that before turning to exogenous hormones—which carry severe risks of infertility and cardiovascular strain—athletes and biohackers must first address the “low-hanging fruit” of physiological inhibition.

The review systematically dismantles and validates various “biohacks.” It confirms that energy deficiency (Relative Energy Deficiency in Sport, or REDs) is a primary, often overlooked castration mechanism in natural athletes. It validates sleep not just as rest, but as the active window of T-synthesis, specifically linked to REM cycles. Crucially, it challenges popular recovery modalities; notably, Cold Water Immersion (CWI) is flagged as potentially counterproductive for hypertrophy and testosterone availability immediately post-training.

Furthermore, the paper elevates the conversation around environmental toxins, positioning Endocrine Disrupting Chemicals (EDCs) like bisphenols and phthalates as invisible suppressors of the Hypothalamic-Pituitary-Gonadal (HPG) axis. It also touches on controversial topics, offering cautious support for supplements like Eurycoma longifolia (Tongkat Ali) while debunking the efficacy of most commercial “testosterone boosters”. Ultimately, this is a manifesto for “subtracting interference” (stress, toxins, deficits) rather than just “adding agonists.”

Source:

  • Open Access Paper: Testosterone-Optimizing Strategies in Athletes
  • Institution: Mayo Clinic, USA
  • Journal: Sports Health: A Multidisciplinary Approach, 2026, Feb 2
  • Impact Evaluation: The impact score of this journal is 2.6 (Impact Factor) and 6.4 (CiteScore), therefore this is a Medium impact journal.

Biohacker Analysis

Study Design Specifications

  • Type: Narrative Review (Level 5 Evidence).
  • Subjects: N/A (Review of existing human and animal literature).
  • Methodology: Database search of PubMed for English-language peer-reviewed articles focusing on legal testosterone enhancement.

Lifespan Analysis

  • Relevance: The interventions discussed (e.g., avoiding EDCs, optimizing sleep) are generally aligned with healthspan extension, but the paper offers no direct mortality data.

Mechanistic Deep Dive

The review highlights specific molecular and systemic pathways regulating the HPG axis:

  • HPG Axis Suppression via Energy Stress: The hypothalamus integrates signals of energy availability. Low Energy Availability (LEA) suppresses Gonadotropin-Releasing Hormone (GnRH) pulses, downstreaming to reduced Luteinizing Hormone (LH) and T production. This confirms that caloric restriction (CR), while pro-longevity in some contexts, is anti-anabolic and anti-androgenic if too severe.
  • Aromatase Inhibition & SHBG Modulation:
    • Eurycoma longifolia is highlighted for its ability to inhibit aromatase (preventing T to Estrogen conversion) and dissociate Free Testosterone (FT) from Sex Hormone Binding Globulin (SHBG).
    • Zinc acts as a cofactor for steroidogenic enzymes and antioxidant defense in Leydig cells, essential only in deficiency states.
  • Cortisol Antagonism: High-intensity resistance exercise acutely spikes T, but chronic stress/cortisol competes with T for receptors and inhibits steroidogenesis. Managing the T:Cortisol ratio is cited as a key anabolic lever.
  • Environmental Toxicity: EDCs (plastics, pesticides) mimic estrogens or block androgen receptors (AR), directly disrupting testicular function.
  • Radiofrequency Electromagnetic Radiation (RF-EMR): The paper suggests a mechanism where RF-EMR (e.g., cell phones in pockets) induces oxidative stress (ROS) in testicular tissue, damaging Leydig cells.

Novelty

  • The “Cold” Warning: Unlike general wellness advice that praises cold plunges, this review specifically warns that post-exercise cold water immersion may blunt the acute testosterone response and downstream hypertrophy signaling. This is a critical nuance for biohackers combining resistance training with cryotherapy.
  • Technological Toxicity: It explicitly categorizes RF-EMR (cell phones) and Blue Light/Sleep disruption as endocrine disruptors, moving them from “wellness speculation” to “clinical consideration” for athletes.
  • Dietary Nuance: It differentiates between healthy fats (pro-T) and high-protein/low-carb diets, noting that excessive protein (>3.4 g/kg) with low carbs may actually lower basal testosterone.

Critical Limitations

  • Low Level of Evidence: As a “Level 5” Narrative Review, the conclusions are based on the authors’ selection of studies rather than a systematic, quantitative meta-analysis.
  • Conflicting Data on “Biohacks”: The evidence for Sauna is deemed “unclear” with studies showing neutral or inconsistent effects on T, despite its popularity in longevity circles. Similarly, the link between RF-EMR and human T levels is inconsistent, relying heavily on rodent data.
  • Translational Gaps: Many mechanistic claims (e.g., Eurycoma mechanisms, specific EDC thresholds) are extrapolated from animal models or small, short-term human trials. The clinical impact of these transient hormonal changes on long-term performance or hypertrophy remains unquantified.
  • Female Data Deficit: The authors explicitly admit that most strategies are extrapolated from male physiology, with significantly less data available for female athletes.

Here is the external verification and hierarchy analysis of the claims made in the paper.

Claims & Verification

Claim 1: “Low Energy Availability (LEA) suppresses the HPG axis, lowering testosterone in men (REDs).”

Claim 2: “Post-exercise Cold Water Immersion (CWI) blunts anabolic signaling and testosterone response.”

  • Evidence Level: Level A (Meta-Analysis)
  • Verification: A systematic review with meta-analysis confirms that CWI following resistance exercise attenuates muscular strength gains and hypertrophy. While some acute hormonal data is mixed, the downstream effect on anabolism is negative.

Citation: Throwing cold water on muscle growth: A systematic review with meta‐analysis of the effects of postexercise cold water immersion on resistance training‐induced hypertrophy (2020)

  • Claim 3: “Eurycoma longifolia (Tongkat Ali) significantly increases testosterone in men.”
    • Evidence Level: Level A- (Systematic Review & Meta-Analysis of RCTs)
    • Verification: A 2022 meta-analysis of RCTs supports a significant improvement in total testosterone (SMD = 1.352) in men receiving Eurycoma longifolia, particularly in hypogonadal subgroups.

Citation: Eurycoma longifolia (Jack) Improves Serum Total Testosterone in Men: A Systematic Review and Meta-Analysis of Clinical Trials (2022)

  • Translational Note: While statistically significant, the absolute clinical magnitude in healthy, eugonadal men remains debated.

Claim 4: “Sleep restriction (specifically total sleep deprivation) lowers testosterone.”

Claim 5: “Cell phone radiation (RF-EMR) lowers testosterone and damages sperm.”

Claim 6: “High-protein (>3.4 g/kg), low-carbohydrate diets decrease testosterone.”

  • Evidence Level: Level A (Systematic Review & Meta-Analysis)
  • Verification: A systematic review identified that “very high protein” diets (>3.4 g/kg/day) combined with low carbohydrates are associated with a significant decrease in testosterone (~5.23 nmol/L). Moderate protein intakes (up to ~3 g/kg) do not show this effect.
  • Citation: High-protein diets and testosterone (2022)
  • Note: This is a crucial threshold. Most “high protein” diets fall well below 3.4 g/kg, making this relevant primarily to extreme biohackers/bodybuilders.

Claim 7: “Ashwagandha increases testosterone and DHEA-S.”

2 Likes
#2

Actionable Intelligence

The Translational Protocol: Testosterone Optimization

This protocol synthesizes the review’s findings with external safety and pharmacokinetic data. It prioritizes “Subtraction before Addition” (removing EDCs, cortisol, and sleep deficits) followed by targeted nutraceutical support.

1. Compound: Eurycoma longifolia (Tongkat Ali)

  • Target: Aromatase inhibition, SHBG reduction, Cortisol modulation.
  • Human Equivalent Dose (HED) Calculation:
    • Source Data: Rat NOAEL (No Observed Adverse Effect Level) is established at 1,000 mg/kg for standardized aqueous extract.
    • Math: 1,000 mg/kg multiplied by (6 divided by 37) = 162 mg/kg HED.
    • Human Safety Ceiling (70kg): 162 multiplied by 70 = approx. 11,340 mg.
    • Effective Dose (RCTs): 200–400 mg/day of standardized root extract (e.g., Physta/LJ100).
    • Insight: The massive gap between the effective dose (400 mg) and the theoretical safety ceiling (11 g) suggests a high safety margin for acute toxicity. However, idiosyncratic hepatotoxicity remains a risk.
  • Pharmacokinetics:
    • Bioavailability: Poor (less than 10.5% oral bioavailability).
    • Half-Life: Short (approx. 1–2 hours).
    • Action: Must be taken in divided doses or standardized to high Eurycomanone content (greater than 1.5%) to overcome poor absorption.
  • Safety Profile:
    • Liver Signal: Rare but documented cases of drug-induced liver injury (DILI).
    • Protocol: Cycle 5 days ON / 2 days OFF to mitigate potential hepatic accumulation. Monitor ALT/AST.

2. Compound: Ashwagandha (Withania somnifera)

  • Target: Cortisol reduction (HPG axis disinhibition), DHEA-S upregulation.
  • Dose: 300–600 mg/day (KSM-66 or Sensoril) or 120 mg (Shoden/High-Withanolide).
  • Pharmacokinetics:
    • Newer formulations (35% withanolide glycosides) show significantly superior bioavailability and sustained release compared to generic root powder.
  • Biomarker Verification:
    • Primary: Serum Cortisol (Target: reduction).
    • Secondary: DHEA-S (Target: increase).

3. Behavioral “Subtraction” Protocol

  • Cold Water Immersion (CWI):
    • Action: PROHIBITED within 4–6 hours post-hypertrophy training. CWI blunts acute anabolic signaling (p70S6K) and satellite cell activity.
  • Sleep:
    • Action: 8+ hours. REM sleep is the primary window for LH pulsatility.

Feasibility & ROI

  • Sourcing:
    • Eurycoma: High risk of adulteration. Must source patented extracts (LJ100, Physta) to ensure eurycomanone content.
    • Ashwagandha: Widely available, low cost.
  • Cost vs. Effect:
    • Eurycoma: Approx. $30–50/month. ROI: Moderate (Variable responder rate).
    • Ashwagandha: Approx. $15/month. ROI: High (Reliable cortisol reduction).
    • Total Protocol: Approx. $65/month.

The Strategic FAQ

1. “You cite a mouse NOAEL of 1,000 mg/kg for Tongkat Ali, but aren’t there reports of liver failure in humans?” Answer: Yes. While the calculated safety ceiling is high, idiosyncratic Drug-Induced Liver Injury (DILI) has been reported in humans. This is likely due to contamination (heavy metals/sildenafil in grey-market products) or individual metabolic variants, rather than intrinsic dose-dependent toxicity of the root itself. You must use a third-party tested source and monitor liver enzymes (ALT/AST).

2. “I’m taking Metformin for longevity. Does this protocol conflict?” Answer: CONFLICT. Metformin significantly lowers total and free testosterone in men. The mechanism is independent of glucose control. If your primary goal is anabolism/T-optimization, Metformin is counter-productive. You are pressing the gas (Tongkat) and the brake (Metformin) simultaneously.

3. “Can I stack this with Rapamycin?” Answer: Likely safe. Rapamycin can induce glucose intolerance (insulin resistance), which Ashwagandha helps mitigate via insulin-sensitizing pathways. There is no direct pharmacokinetic clash (CYP3A4 inhibition by Tongkat is weak/negligible).

4. “Does Tongkat Ali actually raise Testosterone, or just ‘Free’ Testosterone?” Answer: Primarily Free Testosterone. The mechanism is largely displacing T from SHBG and inhibiting aromatization to estrogen. Do not expect a supraphysiological surge in Total T comparable to TRT; expect a functional improvement in bioavailable androgen status.

5. “I use a sauna and cold plunge daily. What is the optimal timing?” Answer: Sauna: Post-workout is fine (and potentially boosting). Cold Plunge: Never post-resistance training. Move CWI to rest days or pre-workout to avoid blunting the inflammatory signals required for hypertrophy and hormonal adaptation.

6. “Will Ashwagandha make me lethargic?” Answer: Possible. It is a GABA-mimetic and can be sedating (“Somnifera” means sleep-inducing). If you experience anhedonia or lethargy, switch dosing to evening only or cycle off.

Image of GABA receptor complex

Shutterstock

7. “How do I verify this is working without a blood test?” Answer: You can’t. Subjective “libido” is a poor proxy for serum testosterone. You need to test Free Testosterone and SHBG at baseline and Week 8.

8. “Is 17-alpha Estradiol compatible with this stack?” Answer: Proceed with caution. Both 17-alpha estradiol and Ashwagandha/Tongkat are metabolized by the liver. While 17-aE is non-feminizing, adding multiple hepatic loads (plus potential “dirty” supplements) increases DILI risk.

9. “What is the ‘Ferrari’ version of this protocol?” Answer: Swap generic extracts for Liposomal delivery systems or specific high-yield extracts (e.g., 10% Eurycomanone, 35% Withanolides). Couple with hCG monotherapy (clinical prescription required) rather than herbal secretagogues for guaranteed LH pulsing.

10. “Why not just take TRT?” Answer: TRT induces testicular atrophy and infertility (azoospermia) by shutting down the HPG axis feedback loop. This protocol preserves and optimizes your endogenous production. If you want fertility and testicular volume, this is the path; if you want guaranteed supraphysiological numbers regardless of biology, TRT is the path.

Interaction Check: Longevity Stack

Compound Interaction Verification Status
Metformin Antagonistic. Metformin lowers serum Testosterone in men. Major Conflict
Rapamycin Synergistic. Ashwagandha may buffer Rapa-induced glucose intolerance. Safe
SGLT2 Inhibitors Additive. Potential hypoglycemia risk if combined with Ashwagandha. Monitor Glucose
17-alpha Estradiol Hepatic Load. Theoretical risk of cumulative liver stress. Monitor Liver
PDE5 Inhibitors Additive. Vasodilation stacking; watch for hypotension. Safe (usually)
1 Like
#3

Hopefully they also mentioned obesity as a driver of low testosterone. I think there are recent studies that show that anti obesity meds can have a normalizing effect Anti-obesity medications can normalize testosterone levels in men | Endocrine Society

I don’t know why ai suggests hcg when it’s worried about shutting down the hpg axis. Hcg shuts down endogenous LH production over time.

These recommendations probably apply to someone with secondary hypogonadism, but will not work for someone with primary hypogonadism.

3 Likes
#4

Interesting study on Feijoa/Pineapple guava fruit I just found:

“Administration of Feijoa fruit extract after CdCl2 injection in rats ameliorated sperm parameters such as sperm count, morphology, motility and sperm viability, increased levels of LH, FSH, prolactin and testosterone and improved testicular histology. According to the results of this study, it was shown that Feijoa can reduce the destructive side effects of CdCl2 on testicular tissue and sex hormones of the pituitary-gonadal pathway.”

1 Like
#5

Testosterone and Atrial Fibrillation: The Goldilocks Zone Gets a Mechanism

This mini-review from the Kansas City VA and University of Kansas Medical Center argues that the relationship between testosterone and atrial fibrillation is U-shaped rather than linear. Too little testosterone and too much both raise the risk of the most common heart rhythm disorder, and the safest zone sits in the middle of the normal range. The authors reconcile a decade of contradictory findings: older observational work linking low testosterone to AF, the 2023 TRAVERSE randomized trial showing an excess of AF in men given testosterone gel, a 106-trial meta-analysis showing no pooled AF signal, and 2025 cell electrophysiology work showing that low and high androgen states cause arrhythmia by two entirely different cellular routes. Their practical conclusion is that testosterone therapy should aim for mid-physiologic levels, roughly 350 to 550 ng/dL, use stable-release formulations, and be preceded by AF risk stratification.

For twenty years the story about testosterone and the heart was simple in the way that wrong stories usually are. Men’s testosterone falls with age, atrial fibrillation rises with age, and a large 2017 study of 76,639 US veterans found that men whose levels were normalized with replacement therapy had fewer new AF diagnoses. Low testosterone looked like the villain.

Then TRAVERSE landed in 2023. It was the trial the field had waited on: 5,246 hypogonadal men aged 45 to 80, all with cardiovascular disease or multiple risk factors, randomized to daily testosterone gel or placebo and followed for a mean of 33 months. The headline result cleared testosterone of the charge that mattered most. Heart attacks, strokes and cardiovascular deaths were no higher on treatment. But buried in the safety endpoints was something nobody had ordered: new atrial fibrillation occurred in 3.5 percent of treated men versus 2.4 percent on placebo, a relative excess of about 45 percent that reached statistical significance.

This review is an attempt to work out what that number means. The authors’ answer is that both camps were partly right, and the resolution is a curve rather than a line. Population data from the UK Biobank and a post-hoc analysis of the ASPREE trial in 4,570 older men found AF risk elevated at both tails of the testosterone distribution, with men in the top two fifths of natural testosterone carrying roughly double the AF risk of men in the middle.

The mechanistic case arrived in 2025 and is the most interesting part of the paper. Work on the atrial inward rectifier potassium current showed that low and high testosterone are proarrhythmic by separate routes. Low androgen states upregulate calcium-handling proteins that make atrial cells fire spontaneously. High androgen states speed up potassium currents, shortening the electrical recovery time of atrial tissue and opening a window for reentrant circuits. Two mechanisms, one curve.

What the review cannot do is settle whether TRAVERSE found a real effect or an outlier. A meta-analysis of 106 placebo-controlled trials covering 15,436 men found no significant pooled AF signal, and a large real-world replication using electronic health records failed to reproduce it. The authors take the position that risk depends on the atrium you start with, and prescribe accordingly: optimize obesity and sleep apnea first, avoid chasing upper-normal levels, prefer gels and long-acting preparations over short-acting injections, and watch hematocrit above all.

Actionable Insights

The single most transferable message is that more is not better. If you or your clinician are managing testosterone, the target should be the middle of the normal range, roughly 350 to 550 ng/dL, not the top of it. Pushing to 700 to 1000 ng/dL buys no additional symptomatic or metabolic benefit in the published data and sits on the rising limb of the AF risk curve.

How large is the risk? In TRAVERSE, 3.5 percent of treated men developed AF versus 2.4 percent on placebo over about three years. That is a relative increase of about 45 percent, but an absolute increase of only 1.1 percentage points, meaning roughly 92 men would need treatment for one extra case of AF. In statistical terms this is a small effect, equivalent to a Cohen’s d of about 0.21. The doubled risk seen in men with naturally high testosterone in the ASPREE analysis is somewhat larger, around d 0.36, and translates to roughly one extra AF case per 100 men per year.

Three practical points follow. Fix the modifiable drivers first, since obesity, sleep apnea, heavy alcohol use and hypertension are stronger AF drivers than testosterone at either tail. Prefer formulations with stable blood levels, since short-acting injections produce supraphysiologic peaks in the first days after a shot. And if your SHBG is abnormal, which is common with obesity, insulin resistance or age, calculated free testosterone is the number that matters, not total testosterone.

Context and Source

  • Open Access Paper: Association of testosterone and testosterone replacement therapy with atrial fibrillation: an updated review.
  • Authors and institutions: Anand Reddy Maligireddy, Shumedha T. Barua, Rajat S. Barua. Department of Cardiovascular Medicine, University of Kansas Medical Center, Kansas City, Kansas, and Divisions of Cardiovascular Medicine and Cardiovascular Research, Kansas City VA Medical Center, Missouri, United States.
  • Journal: Journal of the Endocrine Society, Published 1 September 2026
  • Impact evaluation: The impact score of this journal is 4.4 (2025 Journal Impact Factor; 2025 CiteScore 5.2), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Low impact journal.